Eli Lilly

Lilly ADA

Biotech

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.

Fraiser Kansteiner Jun 6, 2026 3:28pm

Berlin Germany Brandenburg Gate

Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm

Ascidian

Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B

Jun 3, 2026 7:00am

A ballpoint pen rests on top of a stack of documents ready for signing

Lilly locks in vague, 5-program pact with Haisco worth up to $3B

Jun 1, 2026 7:26am

Eli Lilly Lilly

Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome

Jun 1, 2026 3:52am

Eli Lilly booth at ASCO 2026

ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data

May 31, 2026 8:00am